Concentra Group Holdings Parent, Inc. (CON)
(Delayed Data from NYSE)
$19.82 USD
+0.02 (0.10%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $19.80 -0.02 (-0.10%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CON 19.82 +0.02(0.10%)
Will CON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CON
Earnings Preview: Concentra Group (CON) Q2 Earnings Expected to Decline
Concentra (CON) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Concentra Group Holdings Parent, Inc. (CON) Stock Outpacing Its Medical Peers This Year?
CON or MEDP: Which Is the Better Value Stock Right Now?
Wall Street Analysts Believe Concentra (CON) Could Rally 27.1%: Here's is How to Trade
Other News for CON
Bernstein Reaffirms Their Hold Rating on Continental Aktiengesellschaft (CTTAF)
Jefferies Sticks to Its Hold Rating for Continental Aktiengesellschaft (CTTAF)
Select Medical: Despite A Change In The Regulatory Environment, This Prospect Is Worth Considering
Interesting CON Call Options For March 2026
Vanguard Group Inc's Strategic Acquisition in Concentra Group Holdings Parent Inc